Evidence map›Paper›PMID 38154512›Full record

ArticleNeuropharmacology2024

Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones.

Lauren R Fitzgerald, Brenda M Gannon, Donna Walther, Antonio Landavazo, Takato Hiranita, Bruce E Blough, Michael H Baumann, William E Fantegrossi

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Lauren R FitzgeraldDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Brenda M GannonDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Donna WaltherDesigner Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224, USA.
Antonio LandavazoCenter for Drug Discovery, RTI International, Research Triangle Park, NC, 27709, USA.
Takato HiranitaDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
Bruce E BloughCenter for Drug Discovery, RTI International, Research Triangle Park, NC, 27709, USA.
Michael H BaumannDesigner Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224, USA.
William E FantegrossiDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. Electronic address: WEFantegrossi@uams.edu.
National Institutes of Health · USRTI International · USUniversity of Arkansas for Medical Sciences · USThe University of Texas Health Science Center at San Antonio · USUniversity of Arkansas Medical Center · US

Funding

Studies on MDMA and Related CompoundsZIADA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$16.4M
Translational Training in AddictionT32DA022981 · NIDA · UNIV OF ARKANSAS FOR MED SCIS · PI Melissa Jean Zielinski · 2009 to 2026
$6.1M
POTENTIAL TREATMENT MEDICATIONS FOR DRUG ABUSER01DA012970 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI BLOUGH, BRUCE E · 1999 to 2013
$5.5M
IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERSK23DA000523 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GEBO, KELLY A · 2001 to 2005
$794k
Studies on MDMA and Related CompoundsZ01DA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$199k
Intramural NIH HHS Z01 DA000523Intramural NIH HHS ZIA DA000523NIDA NIH HHS K23 DA000523NIDA NIH HHS R01 DA012970NIDA NIH HHS T32 DA022981
6 · The paper itself

Abstract

Substitutions to the phenethylamine structure give rise to numerous amphetamines and cathinones, contributing to an ever-growing number of abused novel psychoactive substances. Understanding how various substitutions affect the pharmacology of phenethylamines may help lawmakers and scientists predict the effects of newly emerging drugs. Here, we established structure-activity relationships for locomotor stimulant and monoamine transporter effects of 12 phenethylamines with combinations of para-chloro, β-keto, N-methyl, or N-ethyl additions. Automated photobeam analysis was used to evaluate effects of drugs on ambulatory activity in mice, whereas in vitro assays were used to determine activities at transporters for dopamine (DAT), norepinephrine (NET), and 5-HT (SERT) in rat brain synaptosomes. In mouse studies, all compounds stimulated locomotion, except for 4-chloro-N-ethylcathinone. Amphetamines were more potent stimulants than their β-keto counterparts, while para-chloro amphetamines tended to be more efficacious than unsubstituted amphetamines. Para-chloro compounds also produced lethality at doses on the ascending limbs of their locomotor dose-effect functions. The in vitro assays showed that all compounds inhibited uptake at DAT, NET, and SERT, with most compounds also acting as substrates (i.e., releasers) at these sites. Unsubstituted compounds displayed better potency at DAT and NET relative to SERT. Para-chloro substitution or increased N-alkyl chain length augmented relative potency at SERT, while combined para-chloro and N-ethyl substitutions reduced releasing effects at NET and DAT. These results demonstrate orderly SAR for locomotor stimulant effects, monoamine transporter activities, and lethality induced by phenethylamines. Importantly, 4-chloro compounds produce toxicity in mice that suggests serious risk to humans using these drugs in recreational contexts.

Indexed as

AlkaloidsCentral Nervous System StimulantsAmphetaminesAnimalsCarrier ProteinsDopamine Plasma Membrane Transport ProteinsHumansMiceNorepinephrine Plasma Membrane Transport ProteinsRatsSerotonin Plasma Membrane Transport ProteinsStructure-Activity RelationshipAlkaloidsAmphetaminesCarrier ProteinscathinoneCentral Nervous System StimulantsDopamine Plasma Membrane Transport ProteinsNorepinephrine Plasma Membrane Transport ProteinsSerotonin Plasma Membrane Transport ProteinsAmphetamineCathinoneStructure activity relationship

Identifiers

PMID38154512
PMCPMC10842458
OpenAlexW4390278018

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.